市场调查报告书
商品编码
1497871
糖尿病足溃疡治疗市场:治疗方法、溃疡类型和最终用途分类 - 全球预测 2024-2030Diabetic Foot Ulcer Treatment Market by Treatment (Antibiotic Medications, Biologics, Therapy Devices), Ulcer Type (Ischemic Ulcers, Neuro-Ischemic Ulcers, Neuropathic Ulcers), End-use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
糖尿病足溃疡治疗市场规模预计2023年为53.5亿美元,2024年达56.9亿美元,预计2030年将达到83.5亿美元,复合年增长率为6.56%。
糖尿病足溃疡 (DFU) 治疗包括旨在预防、诊断和治疗糖尿病足溃疡的根本原因和併发症的各种服务、产品和技术。由于全球糖尿病盛行率不断上升,以及面临慢性伤口风险的人口老化,对糖尿病足溃疡治疗的需求正在扩大。此外,医疗保健专业人员和患者对有效 DFU 管理的认识不断提高,也导致了晚期糖尿病足溃疡的普及。先进 DFU 治疗产品的高成本阻碍了该治疗的普及并抑制了市场成长。透过生物工程皮肤替代、干细胞疗法、基于生长因子的疗法和伤口护理(NPWT)等创新技术,糖尿病足溃疡治疗的技术进步预计将为市场成长创造机会。
主要市场统计 | |
---|---|
基准年[2023] | 53.5亿美元 |
预测年份 [2024] | 56.9亿美元 |
预测年份 [2030] | 83.5亿美元 |
复合年增长率(%) | 6.56% |
区域洞察
随着人口老化面临慢性伤口的风险,美国人口中糖尿病的盛行率不断增加,对糖尿病足溃疡治疗的需求也不断扩大。据加拿大健康研究所(CIHR)称,到2021年,将有超过300万加拿大人,即总人口的8.8%,被诊断出患有糖尿病,其中6.1%的加拿大成年人面临患糖尿病的高风险。墨西哥、阿根廷、巴西和智利等新兴经济体的糖尿病正在迅速蔓延,大多数糖尿病患者尚未确诊。政府为改善整个欧洲 DFU 治疗的可近性而采取的重大倡议预计将为市场成长奠定基础。该地区的主要参与者正在为先进且具有成本效益的 DFU治疗方法的开发做出贡献。由于需要更好治疗的糖尿病患者数量显着增加以及人们对其管理的认识不断提高,亚太地区的糖尿病足溃疡市场呈现出先进的态势。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在糖尿病足溃疡治疗市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对糖尿病足溃疡治疗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对糖尿病足溃疡治疗市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[184 Pages Report] The Diabetic Foot Ulcer Treatment Market size was estimated at USD 5.35 billion in 2023 and expected to reach USD 5.69 billion in 2024, at a CAGR 6.56% to reach USD 8.35 billion by 2030.
The diabetic foot ulcer (DFU) treatment includes a range of services, products, and technologies designed to prevent, diagnose, and treat the underlying causes and complications of diabetic foot ulcers. The increasing prevalence of diabetes globally, coupled with an aging population at risk for chronic wounds, is expanding the need for diabetic foot ulcer treatment. Additionally, growing awareness about effective DFU management among healthcare professionals and patients is contributing to the increase in the adoption of advanced diabetic foot ulcers. High costs associated with advanced DFU treatment products hinder the widespread adoption of treatment, thereby hampering market growth. Rising technological advancements in diabetic foot ulcer treatment with innovations such as bioengineered skin substitutes, stem cell therapy, growth factor-based therapies, and negative pressure wound therapy (NPWT) are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 5.35 billion |
Estimated Year [2024] | USD 5.69 billion |
Forecast Year [2030] | USD 8.35 billion |
CAGR (%) | 6.56% |
Regional Insights
The growing prevalence of diabetes among America's population, with an aging population at risk for chronic wounds, is expanding the need for diabetic foot ulcer treatment. As per the Canadian Institutes of Health Research (CIHR), in 2021, over 3 million Canadians, or 8.8% of the population, have been diagnosed with diabetes, and 6.1% of Canadian adults were at high risk of developing diabetes. Developing economies, including Mexico, Argentina, Brazil, and Chile, observe a rapid prevalence of diabetes disorders with a majority presence of undiagnosed diabetic patients. Significant governmental efforts to improve the accessibility of DFU treatment across Europe are expected to create a platform for market growth. The key players in the region are contributing to develop advanced and cost-effective DFU treatments. The Asia-Pacific showcases an advanced landscape for the diabetic foot ulcer market owing to a significant rise in diabetic patients requiring better treatment and surging awareness regarding its management among the population.
Market Insights
The market dynamics represent an ever-changing landscape of the Diabetic Foot Ulcer Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Diabetic Foot Ulcer Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Diabetic Foot Ulcer Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Researchers develop 3D printed bandage that delivers innovative treatment for diabetic foot ulcers
Researchers at Queen's University Belfast developed a groundbreaking 3D printed bandage for the treatment of diabetic foot ulcers (DFUs). The bandage, also known as a scaffold, combines lipid nanoparticles and hydrogels to create personalized skin-like 3D printed scaffolds. These scaffolds have the ability to release antibiotic-loaded molecules in bulk and sustainably. [Published On: 2023-07-27]
Healthium launches Theruptor Novo for diabetic foot ulcers
Healthium Medtech introduced Theruptor Novo, a new wound dressing portfolio designed for the treatment of chronic wounds, such as leg ulcers and diabetic foot ulcers. This wound dressing is antimicrobial and non-toxic, incorporating patented technology that has been recognized in the U.S., India, EU, and Canada. This product effectively reduces the development of resistant microbes and promotes the healing process by utilizing a physical kill mechanism. [Published On: 2022-10-11]
Smith+Nephew announces new study showing GRAFIX Membrane cut the rate of diabetic foot ulcer recurrence in half compared to competitors
Smith+Nephew's GRAFIX Cryopreserved Placental Membrane has been proven to reduce diabetic foot ulcer recurrence rates by up to 58.5% compared to competitors, according to a study. It found a statistically significant reduction in ulcer recurrence and new ulcer formation at all time periods for GRAFIX compared to cellular and acellular CTP groups. [Published On: 2022-03-31]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Diabetic Foot Ulcer Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Diabetic Foot Ulcer Treatment Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Adocia SA, Alkem Laboratories Ltd., B. Braun SE, Cardinal Health, Inc., Centaur Pharmaceuticals Private Limited, Cipla Limited, Coloplast Corp., ConvaTec, Inc., Essity AB, GlaxoSmithKline PLC, Healthium Medtech Limited, Integra LifeSciences Corporation, Medline Industries, Inc., MIMEDX, Inc., Molnlycke Health Care AB, Organogenesis, Inc., PAUL HARTMANN AG, Pristyn Care, Reapplix A/S, SANUWAVE Health, Inc., SIGVARIS Group, Smith & Nephew PLC, SynerHeal Pharmaceuticals, Tissue Regenix Ltd., and URGO Medical, Australia Pty Ltd..
Market Segmentation & Coverage